Marvel’s lead compound (MB-204) is a novel fluorinated derivative of Istradefylline, the only clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson’s disease.

However, Marvel is developing MB-204 for diseases other than Parkinson’s disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Each disease area represents a multi-billion market with high, unmet medical need. By modifying a known approved drug with logical chemical changes, coupled with the potential to develop the drug for multiple unrelated diseases, Marvel believes it significantly de-risks its drug development efforts.


Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases

Read full article here: https://pubmed.ncbi.nlm.nih.gov/34635103/


CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease

Read full article here: https://pubmed.ncbi.nlm.nih.gov/34033815/


Proposed Development Timeline:



Complete cGMP run of MB-204 for clinic

Complete dose ranging dog and rat studies



Begin rat and dog GLP toxicology studies

Begin Design of Phase 1 Clinical Trials



Complete Pre-clinical Toxicology Studies

Planning Phase 1 and 2 clinical trials of MB-204



Phase 1 SAD clinical trial results of MB-204 includes placebo and efficacy endpoints

Accelerate partnership talks

MB-204 – A potential solution to a growing Alzheimer’s and Depression market


*Note: timelines may be subject to change.

Marvel Non-Hallucinogenic Neuroplasticity Program

Marvel has identified a series of related compounds that appear to be potent, fast acting, water soluble and orally available small tryptamine derivatives that have anti-depressive activity but no overt hallucinatory activity in pilot studies.

Second Program: Safer Neuroplastic Promoting Drugs


Marvel has identified a set of molecules inspired by the tryptamine class of psychedelics that are:


  • Fast acting anti-depressants
  • Orally available
  • Water soluble
  • No evidence of hallucinations
  • Lead better than fluoxetine (Prozac, p<0.005)